Diagnostic tools for AD include comprehensive clinical evaluations, cognitive assessments, laboratory tests, neuroimaging (such as MRI, PET scans), and biomarker testing (such as cerebrospinal fluid analysis for amyloid-beta and tau proteins) [150]. This evidence concerns the gene MAPT and Alzheimer disease.